You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Rituximab for the first-line treatment of stage III-IV follicular lymphoma

  • Technology appraisal guidance
  • Reference number: TA243
  • Published:  25 January 2012
  • Guidance
  • Tools and resources
  • Information for the public
  • History

TA243 Follicular lymphoma - rituximab (review): appendix a - decision paper presented to the Institute's Guidance Executive

TA243 Follicular lymphoma - rituximab (review): appendix a - decision paper presented to the Institute's Guidance Executive TA243 Follicular lymphoma - rituximab (review): appendix a - decision paper presented to the Institute's Guidance Executive
26 August 2014
(106.59 Kb 31 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 26 August 2014

Back to top